Although the use of bisphosphonates is a well-established form of supportive care treatment for bone metastasis, complications arising from long-term use require schedule optimization and a search for alternative strategies. A recent study (Clin Cancer Res 2010 Aug 3) from the Massachusetts General Hospital Cancer Center, looked at studies optimizing bisphosphonate use and recent clinical data on denosumab in the treatment of bone disease. The study also provided insight into the preclinical rationale and clinical assessment of novel antiresorptive and anabolic bone-targeted agents.
Details available at:
Novel Bone-Targeted Strategies in Oncology
Denosumab protects bones better than zoledronic acid(Drug information on zoledronic acid) in metastatic disease
The Role of Bisphosphonates in the Adjuvant Setting for Breast Cancer